Study design. Design included leukemia harvest at diagnosis of AML, induction chemotherapy with high-dose cytarabine (Ara-C) and daunorubicin (Dauno), consolidation chemotherapy with high-dose Ara-C and etoposide (VP16), followed by stem cell mobilization with GCSF, peripheral blood stem cell (PBSC) collection, single pretransplantation dose of immunotherapy, followed by collection of primed lymphocytes by lymphapheresis, pretransplantation myeloablative preparative regimen with Busulfan (Bu) and cyclophosphamide (Cy), PBSC and primed lymphocyte infusion, and posttransplantation immunotherapy treatments administered every 3 weeks for 8 doses, beginning at least 6 weeks after transplantation.